From IgE to Anti‐IgE: Where do we stand?

Hamelmann, Eckard; Rolinck-Werninghaus, Claudia; Wahn, Ulrich

doi:10.1034/j.1398-9995.2002.02165.x

Cited by 24 publications

(9 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…IgE production involves activation of effector cells, mainly mast cells and basophils, leading to an inflammatory response and specific clinical manifestations. 9 Currently, the only effective treatment for this is avoidance of the food in question. Total avoidance is difficult because sesame is used in many foods, and accidental consumption is almost unavoidable.…”

mentioning

confidence: 99%

Identification and characterization of linear B-cell epitopes of β-globulin, a major allergen of sesame seeds

Wolff¹,

Yannai²,

Karin

et al. 2004

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

mentioning

confidence: 99%

Identification and characterization of linear B-cell epitopes of β-globulin, a major allergen of sesame seeds

Wolff¹,

Yannai²,

Karin

et al. 2004

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

“…By studying children allergic to grass pollen, the comparison of subjects treated with a combination of omalizumab and immunotherapy with those treated with monotherapies by either anti-IgE or grass immunotherapy showed a higher efficacy of the combined treatment (Rolinck-Werninghaus 2004). An apparent advantage of adding omalizumab to allergen immunotherapy is that anti-IgE treatment is not allergen specific and thus is effective also on symptoms induced by other allergens in polysensitized patients (Hamelman et al 2002). …”

Section: Anti-ige and Allergen Immunotherapymentioning

confidence: 99%

Current and future applications of the anti-IgE antibody omalizumab

Incorvaia¹,

Mauro²,

Riario-Sforza³

et al. 2008

BTT

View full text Add to dashboard Cite

IgE antibodies are a pivotal factor in pathophysiology of allergic diseases, and the possibility of reducing their level by anti-IgE has long been envisioned. Following several attempts, an effective biologic agent was obtained with the recombinant humanized mono-clonal antibody (rhuMAb)-E25, known as omalizumab. A number of controlled clinical trials demonstrated its efficacy and safety in the treatment of severe allergic asthma uncontrolled by standard drug treatment with maximal recommended doses, and treatment with omalizumab is currently included in international guidelines on asthma management. Other studies reported a clear effectiveness also in allergic rhinitis, but the cost of the anti-IgE treatment suggests its use in patients with rhinitis concomitant with asthma. Other indications to be further investigated are skin disorders such as atopic dermatitis and IgE-mediated urticaria, as well as adverse reactions to foods, with a particularly important role in preventing food-induced anaphylaxis. Finally, there are data indicating the usefulness of omalizumab when used in combination with allergen specific immunotherapy, in terms of reducing the adverse reactions to treatment and increasing the clinical efficacy.

show abstract

“…Several clinical studies using recombinant humanised monoclonal ANTIBODY to human IgE (E25, Xolair, Omalizumab) have been conducted and published (reviewed in [43]). …”

Section: Clinical Trialsmentioning

confidence: 99%